IP Library Granted Patent US 9,421,207
Granted Patent B2
US 9,421,207 · App. 14/403,310 · Granted Aug 23, 2016

Pharmaceutical compositions comprising pemetrexed and tromethamine

Inventors: Dhiraj Khattar (Gurgaon, IN); Rajesh Khanna (Gurgaon, IN); Mukti Yadav (Gurgaon, IN); Krishanu Burman (Gurgaon, IN)
Assignee: FRESENIUS KABI ONCOLOGY LIMITED
A61K31/519A61K9/0019A61K9/19A61K47/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,421,207
App. No.
14/403,310
Granted
Aug 23, 2016
Kind
B2
Abstract

A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention.

Claims (20)

1. A lyophilized pharmaceutical composition comprising pemetrexed of formula I,

tromethamine, nitrogen, and a pharmaceutically acceptable excipient, wherein the tromethamine is present at 40% to 90% by weight of the pemetrexed.

2. The pharmaceutical composition according to claim 1 , wherein the excipient is an antioxidant, a chelating agent, an amino acid, a preservative, a bulking agent, a buffer, an organic solvent, a carrier, a diluent a solubilizer, or a combination thereof.

3. The pharmaceutical composition according to claim 2 , wherein the antioxidant is monothioglycerol, L-cysteine, thioglycolic acid, sodium metabisulfite, ascorbic acid, sodium ethylenediaminetetraacetic acid, monoethanolamine gentisate, sodium formaldehyde sulfoxylate, sodium bisulfate, or a combination thereof.

4. The pharmaceutical composition according to claim 2 , wherein the chelating agent is ethylenediaminetetraacetic acid.

5. The pharmaceutical composition according to claim 2 , wherein the amino acid is glutamic acid or histidine.

6. The pharmaceutical composition according to claim 2 , wherein the preservative is phenylmercuric nitrate, thiomersal, benzalkonium chloride, benzethonium chloride, phenol, cresol or chlorobutanol.

7. The pharmaceutical composition according to claim 2 , wherein the bulking agent is dextrose, sucrose, mannose, mannitol, or a combination thereof.

8. The pharmaceutical composition according to claim 2 , wherein the buffer is acetate, citrate, tartrate, phosphate, benzoate, bicarbonate, or a combination thereof.

9. The pharmaceutical composition according to claim 2 , wherein the organic solvent is propylene glycol, N,N-dimethylacetamide, or ethanol.

10. The pharmaceutical composition according to claim 1 , wherein the tromethamine is present at 60% by weight of the pemetrexed.

11. The pharmaceutical composition according to claim 10 , wherein the composition further comprises a bulking agent at 100% by weight of the pemetrexed.

12. The pharmaceutical composition according to claim 1 , wherein the composition further comprises an aqueous 5% dextrose solution or an aqueous 0.9% sodium chloride solution.

13. A process for preparing the pharmaceutical composition according to claim 1 , comprising the steps of:

a) adding water to a vessel;

b) adding tromethamine and a bulking agent to the water;

c) adding pemetrexed to the aqueous solution of step b);

d) adjusting the solution of step c) to a pH in the range of 6 to 8; and

e) lyophilizing the solution of step d) in the presence of nitrogen.

14. The process according to claim 13 , wherein step a) further comprises purging the water with nitrogen gas.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2014
From: KHATTAR, DHIRAJ; KHANNA, RAJESH; YADAV, MUKTI; BURMAN, KRISHANU
To: FRESENIUS KABI ONCOLOGY LIMITED
Reel/Frame 034250/0364 →
Priority Claims (1)
IN 1648/DEL/2012 · May 30, 2012 · national
Continuity (1)
Related Publication 20150111905A1 · Apr 23, 2015